$RZRA · Rezera Inc.
Rezera Inc. (formerly NodThera Inc.) filed Amendment No. 2 to its S-1 to offer 16,666,667 shares of common stock at an expected price of $11.00–$13.00 per share, with a 30-day underwriters' option for up to 2,500,000 additional shares. The clinical-stage biotech develops oral NLRP3 inhibitors, led by ruvonoflast for peripheral artery disease (PAD). GSK affiliate Glaxo Group Limited has indicated interest in purchasing up to 2,083,333 shares (up to $25.0M at the $12.00 midpoint), roughly 10% of post-offering shares outstanding.
- Offering of 16,666,667 shares at $11.00–$13.00 per share, with a 30-day option for 2,500,000 more shares.
- GSK indicated interest in up to 2,083,333 shares, up to $25.0M at the $12.00 midpoint.
- Lead candidate ruvonoflast reduced hsCRP by 82% versus 37% placebo in a calorie-restricted high-CV-risk trial.
- RESOLVE-1 Phase 2 showed hsCRP reductions of 56.4% (150 mg QD) and 62.6% (150 mg BID) at week 4.
- Company changed its name from NodThera Inc. to Rezera Inc. effective September 9, 2026.
Price data unavailable.
A clinical-stage NLRP3 biotech with a GSK strategic interest is moving toward a Nasdaq IPO ahead of a pivotal Phase 3 PAD trial.
Rezera joins a wave of inflammation-focused biotechs targeting residual inflammatory risk (RIR) in cardiovascular disease, competing conceptually with NLRP3 and IL-1β/IL-6 pathway players.
No clinical trials of ruvonoflast have been conducted in PAD patients; all supporting data come from other indications. GSK's interest is non-binding and may result in fewer or no shares purchased.